RAD - Radiopharm welcomes positive guidance from FDA to advance Pivalate

(NewsDirect)

Radiopharm Theranostics Ltd (ASX:RAD) CEO Riccardo Canevari speakswith Proactive after the company completed a positivepre-Investigational New Drug (IND) meeting with the US Food and DrugAdministration (FDA) for its proprietary imaging agent, F18-pivalate(RAD 101). He says it’s a significant milestone towardsRadiopharm’s IND application for late-stage clinical trials. InOctober 2022, positive data from the Imperial College of London’sPhase IIa imaging trial of RAD 101 in patients with brain metastasesshowed significant tumour uptake consistent with and independent fromthe tumour of origin.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.